Novel treatment paradigms for immune-mediated and inflammatory conditions  

Our two Ph2 stage first-in-class and novel mode of action drug candidates are pipeline generators as they each have multiple indications potential (“I&I pipeline in a product”):

MC2-32: Oral HSP90 Inhibitor with unique pharmacological profile targeting multiple pro-inflammatory pathways and relevant immune responses while uniquely demonstrating a favorable safety profile.

MC2-25: Iso-cyanate Scavenger addressing non-enzymatic posttranslational protein and amino acid modification (carbamylation) in the skin by iso-cyanate, a dissociation product of urea.

We are currently pursuing indications where there are none or very limited approved treatment options including oral MC2-32 for Hidradenitis Suppurativa (Ph2a completed) and MC2-25 for Chronic Kidney Disease-associated Pruritus (Ph2 enrollment completed, n=111) and MC2-25 for Vulvar Lichen Sclerosus (Ph2a ongoing).

We also apply our expertise in formulation and clinical practice to ensure treatment satisfaction for the patients and release of the full clinical potential of therapies.

MC2-32 HS

Read more

Active ingredient: HSP90 inhibitor 
Indication: Hidradenitis Suppurativa

MC2-25 CKD-aP

Read more

Active ingredient: Iso-cyanate scavenger
Indication: CKD-aP (Stage 3-5)

MC2-25 VLS

Read more

Active ingredient: Iso-cyanate scavenger
Indication: Vulvar Lichen Sclerosus